Study details
Enrolling now
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
NCT IDNCT05657873ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
68
Study length
about 3 years
Ages
18+
Locations
9 sites in FL, NJ, NY +1
About this study
This trial is testing whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Anti-PD-(L)1 based immunotherapy
- 2.Receive L-SABR
- 3.Take Platinum based chemotherapy
PhasePhase 2
DrugAnti-PD-(L)1 based immunotherapy
Primary goalMedian progression-free survival
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
immunotherapy
Endpoints
Primary: Median progression-free survival
Body systems
Oncology